Trial Profile

A Phase 2 Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Adults With Head and Neck Cancer

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 06 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ADU-S100 (Primary) ; Pembrolizumab (Primary)
Indications Head and neck cancer; Squamous cell cancer
Focus Therapeutic Use
Sponsors Chinook Therapeutics

Most Recent Events

03 Dec 2021 Status changed from active, no longer recruiting to discontinued.
08 Mar 2021 Planned End Date changed from 1 Jan 2022 to 1 Dec 2022.
08 Mar 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com